Opus Genetics IRD 深 沪
等待开盘 08-22 09:30:00 美东时间
4.05
-0.070
-1.70%
华盛通- 最 高4.33
- 今 开4.16
- 成交量 104.49万股
- 最 低 4.02
- 昨 收 4.12
- 总市值 3.37亿
- 52周最高 5.81
- 市盈率 静 --
- 换手率 1.26%
- 52周最低 1.22
- 委 比 -48.70%
- 总股本 8319.58万
- 历史最高 23.08
- 量 比 1.32
- 振 幅 7.52%
- 历史最低 0.65
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...
08-19 20:05
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced that its Compensation Committee approved equity awards under the 2021 Inducement Plan for three non-executive employees. The awards, totaling 310,000 stock options, vest over four years and align with Nasdaq Listing Rule 5635(c)(4). The company focuses on gene therapies to restore vision and prevent blindness, with a pipel...
08-19 20:01
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
08-08 04:00
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $755.000 thousand ...
08-06 19:29
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating
TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating.
07-29 22:29
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.
07-07 00:54
Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29
Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-mar...
06-26 21:17
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
